申请人:Novo Nordisk A/S
公开号:US20140179899A1
公开(公告)日:2014-06-26
The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1(7-37), and a maximum of ten amino acid modifications as compared to GLP-1(7-37), wherein the first K residue is designated K
37
, and the second K residue is designated K
26
, which derivative comprises two albumin binding moieties attached to K
26
and K
37
, respectively, wherein the albumin binding moiety comprises a protracting moiety selected from:
Chem. 1, Chem. 2, Chem. 3 or Chem. 4; or a pharmaceutically acceptable salt, amide, or ester thereof.
本发明涉及一种GLP-1类似物的衍生物,该类似物包括第一个K残基,位于与GLP-1(7-37)(SEQ ID NO:1)的37位相对应的位置,第二个K残基,位于与GLP-1(7-37)的26位相对应的位置,并且与GLP-1(7-37)相比,最多具有十个氨基酸修饰,其中第一个K残基被指定为K37,第二个K残基被指定为K26,该衍生物包括连接到K26和K37的两个白蛋白结合基团,其中白蛋白结合基团包括从以下选择的伸长基团:化学式1、化学式2、化学式3或化学式4;或其药学上可接受的盐、酰胺或酯。